hotspot -WSS

hotspot

author：comprehensive 2025-09-27 23:51:59 - browse：1321

Perrigo Opill press photo – pharma coverage from STAT — Opill, the first over-the-counter birth control pill, is on its way to U.S. stores. Perrigo via AP

WASHINGTON — The first over-the-counter birth control pill will be available in U.S. stores later this month, allowing American women and teens to purchase contraceptive medication as easily as they buy aspirin.

Manufacturer Perrigo said Monday it has begun shipping the medication, Opill, to major retailers and pharmacies. A one-month supply will cost about $20 and a three-month supply will cost around $50, according to the company’s suggested retail price. It will also be sold online.

The launch has been closely watched since last July, when the Food and Drug Administration said the once-a-day Opill could be sold without a prescription. Ireland-based Perrigo noted there will be no age restrictions on sales, similar to other over-the-counter medications.

Opill is an older class of contraceptive, sometimes called minipills, that contain a single synthetic hormone, progestin, and generally carry fewer side effects than more popular combination estrogen and progestin pills.

Newsletters

Sign up for Morning Rounds

Understand how science, health policy, and medicine shape the world every day

Please enter a valid email address. Privacy Policy

The launch gives U.S. women another birth control option amid the legal and political battles over reproductive health, including the reversal of Roe v. Wade, which has upended abortion access across the U.S. Opill’s approval is unrelated to the ongoing court battles over the abortion pill mifepristone. And anti-abortion groups have generally emphasized that they do not oppose contraceptives to prevent pregnancies.

Birth control pills are available without a prescription across much of South America, Asia, and Africa.

The drug’s approval came despite some concerns by FDA scientists about the company’s results, including whether women with certain medical conditions would understand that they shouldn’t take the drug.

Dr. Verda Hicks, president of the American College of Obstetricians and Gynecologists, in a statement, said studies have shown that patients, including adolescents, can effectively screen themselves to use the pills.

— Matthew Perrone

Previous article： Sports medicine is finally prioritizing gender equality
Next article： US judge blocks portions of new Florida elections law

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

JPM: CVS says Medicare Advantage patients are impacting profits

Federal weight loss drug coverage is 30 years out of date

A timeline of the missing Titanic tourist submersible

knowledge

hotspot

Sign up for Morning Rounds

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Goldman Sachs launches $650M fund for life science investments

Malaria cases in Florida and Texas: Here’s what you need to know

3 medical device trends to watch in 2024

Dobbs anniversary: the lost opportunity of abortion as health care

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

United colonoscopy coverage change 'may cost lives,' doctors say

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Moonlake's readout produced a cash windfall. Risks remain

EU climate chief is concerned over the expansion of the coal industry in China

Wikipedia

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

4 dead, 2 in stable condition in Philadelphia shooting: Police

10 states plan to sue EPA over standards for residential wood

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

Elon Musk announces 'temporary limits' for reading Twitter posts

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

entertainment

entertainment

leisure time